Healthcare Capital Partners - Portfolio of Investments

Stheno Corporation was founded on June 24th of 2003 by Phillip Gibbs and William Edens to enhance the quality and safety of consumer chemical products with a specific focus on the pharmaceutical industry. Stheno is a privately owned C type corporation operating in Atlanta, Georgia. The technology at Stheno's heart is a patent pending chemical detection system termed Magneto-Optical Enantiomeric Detection or MOPED™. MOPED™ is a platform technology that will allow sensitive detection of chiral molecules in solution.

Stheno has assembled a top-notch team of engineers, scientists, and programmers with expertise ranging from biochemistry to optical physics. This team is responsible for the groundbreaking innovations that make Stheno’s core technology the powerful analytical platform that it is today.

Stheno Corporation has assembled a top-notch team of engineers, scientists and programmers with expertise ranging from biochemistry to optical physics. This team is responsible for the groundbreaking innovations that make MOPED technology the powerful analytical platform that it is today.

Alveolus provides medical stent technology in the emerging field of non-vascular interventional stenting. The company, whose products are developed by physicians for physicians, is designing, manufacturing and testing a Stent Technology System (STS) and other advanced devices for the battle against cancerous and benign obstructive lumen disease.

Alveolus is developing a next-generation stent for use in the lungs. The company is working in various stages of development for stents for use in the esophagus, colon, duodenum, pancreas, biliary tract and other ducts.

Valeo Medical, Inc.

Valeo Medical is a Life Sciences company founded in 2003 to develop the world's first non-invasive diagnostic - a blood test - for endometriosis, a chronic, painful disease which affects one out of ten women of child bearing age. The same technology could also lead to the first non-hormonal therapeutic for the condition. These products will address the needs of millions of women who suffer with endometriosis and currently have very few options for diagnosis and treatment of their condition.

GeneEx is developing rapid, point-of-care diagnostic tests for infectious diseases capable of detecting virulence markers produced ONLY during active infections. Unlike current diagnostic assays, GeneEx's tests can detect pathogens in action as opposed to when they are just harmless colonizers. GeneEx will focus its initial commercialization effort on infectious diseases such as periodontitis, group A strep and systemic fungal infections. With a unique combination of patented technologies, an experienced management team, a gifted scientific and advisory team and products with shortened regulatory pathways, GeneEx is poised to make a substantial impact in the medical community.

The Company is developing innovative, implantable devices that repair heart valve abnormalities.  MitralSolutions believes that there are substantial market opportunities in both the surgical and percutaneous applications and is developing a product portfolio that will address treating a greater number of patients earlier in their disease cycle, providing an improved quality of life.